A new study suggests that SGLT2 inhibitors,medications originally developed to treat diabetes,may be more effective than newer heart failure drugs for elderly patients with both frailty adn heart failure with preserved ejection fraction (HFpEF). HFpEF, a common condition especially affecting seniors, has historically been tough to treat [[1]]. The research, published recently in Medscape, indicates a potential shift in treatment protocols for this vulnerable population, offering hope for improved outcomes [[2]].
SGLT2 Inhibitors Show Benefit Over ARNi in Elderly Patients with Heart Failure
For older adults with frailty and heart failure with preserved ejection fraction (HFpEF), a class of diabetes drugs known as SGLT2 inhibitors appear to offer greater benefits than a newer class of heart failure medications called ARNi (angiotensin receptor-neprilysin inhibitors), according to recent research. This finding is significant as HFpEF is a common and often challenging-to-treat form of heart failure, particularly in aging populations.
The study, detailed in Medscape, investigated the effectiveness of these two treatment approaches in a vulnerable patient group.
Researchers found that SGLT2 inhibitors demonstrated a superior effect compared to ARNi in this specific population. The study focused on elderly individuals experiencing frailty alongside HFpEF, a combination that often leads to poorer outcomes and increased healthcare needs.
“These findings suggest that SGLT2 inhibitors may be a more effective treatment option for older, frail patients with HFpEF,” researchers said. The results could influence clinical guidelines and treatment decisions for this growing patient population.
Further research is ongoing to fully understand the mechanisms behind these observed differences and to determine the optimal treatment strategies for elderly patients with HFpEF. The findings underscore the importance of tailoring heart failure treatment to the individual characteristics and vulnerabilities of each patient.
